Furthermore, they revealed that CHIP is a modifiable risk factor for MASLD by enhancing NLR family pyrin domain-containing protein 3 (NLRP3) inflammasome and its downstream inflammatory cytokines [35]. Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.